Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -4,7 +4,7 @@
4	4
5	5	= =
6	6
7		-OncoSec Medical is a biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. The company's core platform technology, ImmunoPulse®, is a drug-device therapeutic modality comprised of a proprietary intratumoral electroporation delivery device. The ImmunoPulse® platform is designed to deliver DNA-encoded drugs directly into a solid tumor and promote an inflammatory response against cancer. The ImmunoPulse® device can be adapted to treat different tumor types, and consists of an electrical pulse generator, a reusable handle and disposable applicators. The company's lead product candidate, ImmunoPulse® IL-12, uses its electroporation device to deliver a DNA-encoded interleukin-12, or IL-12, called tavokinogene telseplasmid, or tavo, with the aim of reversing the immunosuppressive microenvironment in the tumor and engendering a systemic anti-tumor response against untreated tumors in other parts of the body.
	7	+OncoSec Medical (ONCS) is a biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. The company's core platform technology, ImmunoPulse®, is a drug-device therapeutic modality comprised of a proprietary intratumoral electroporation delivery device. The ImmunoPulse® platform is designed to deliver DNA-encoded drugs directly into a solid tumor and promote an inflammatory response against cancer. The ImmunoPulse® device can be adapted to treat different tumor types, and consists of an electrical pulse generator, a reusable handle and disposable applicators. The company's lead product candidate, ImmunoPulse® IL-12, uses its electroporation device to deliver a DNA-encoded interleukin-12, or IL-12, called tavokinogene telseplasmid, or tavo, with the aim of reversing the immunosuppressive microenvironment in the tumor and engendering a systemic anti-tumor response against untreated tumors in other parts of the body.{{footnote}}https://fintel.io/doc/sec-oncs-oncosec-medical-10k-2018-october-19-17962{{/footnote}}
8	8
9	9	The company's current focus is to pursue its registration-directed study of ImmunoPulse® IL-12 in combination with an approved therapy for melanoma in patients who have shown resistance to or relapse from certain other cancer therapies, which the company refer to as the PISCES study. Most of its present activities are directed toward advancing the PISCES study. The company also intend to continue to pursue other ongoing or potential new trials and studies related to ImmunoPulse® IL-12, all with the goal of obtaining requisite regulatory approvals from the U.S. Food and Drug Administration, or FDA, and comparable regulators in certain other jurisdictions to market and sell this product candidate.
10	10
...	...	@@ -101,3 +101,5 @@
101	101	The company expect to use its available working capital in the near term primarily for the advancement of its existing and planned clinical programs, including primarily the initiation of the PISCES/KEYNOTE-695 study and, to a lesser extent, the continuation of its other clinical trials and studies described above. The company anticipate its spending on clinical programs and the development of its next-generation electroporation device for its ImmunoPulse® IL-12 platform will increase throughout its current fiscal year, primarily in support of the PISCES/KEYNOTE-695 study, while its spending on research and development programs will decrease due to its focus on the PISCES/KEYNOTE-695 study. The company expect its cash-based general and administrative expenses to remain relatively flat in the near term, as the company seek to continue to leverage internal resources and automate processes to decrease its outside services expenses. See “Results of Operations” below for more information.
102	102
103	103	= References =
	104	+
	105	+{{putFootnotes/}}